Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
about
Optimal delivery of male breast cancer follow-up care: improving outcomesDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsManagement of endocrine disease: Secondary osteoporosis: pathophysiology and managementBone targeted therapies for the prevention of skeletal morbidity in men with prostate cancerCancer treatment-related bone disease.A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial.A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer.A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma.Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an updateSkeletal response to resistance and impact training in prostate cancer survivors.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Bone health and prostate cancer.Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancerEffects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancerManagement of complications of prostate cancer treatment.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancerContemporary role of androgen deprivation therapy for prostate cancerMedication-induced osteoporosis: screening and treatment strategiesRadiotherapy combined with hormonal therapy in prostate cancer: the state of the art.Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study.Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.Intervening on the side effects of hormone-dependent cancer treatment: the role of strength training.Denosumab in men receiving androgen-deprivation therapy for prostate cancerAndrogen deprivation therapy for prostate cancer: new concepts and concerns.The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumorsRandomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.NCCN Task Force Report: Bone Health in Cancer Care.Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.Update on medications with adverse skeletal effectsManagement of complications of androgen deprivation therapy in the older man.Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksBone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia.RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis.Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancerBone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in boneEfficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States.
P2860
Q26773195-7C1A0124-4E73-4D6E-B360-E10BF0AB8047Q26824762-0B637887-F9FE-4850-A1BE-620CB8EB959CQ26998249-49BFC80C-73B4-440C-9277-3D97EE2AFE69Q27021268-F385BB00-6173-4739-A38F-D9F31254B6D3Q30438185-F1907075-7DE8-4B85-9AAD-90531E386225Q30936900-8B6E5DB2-3FB6-45B9-92A9-88E7967B6265Q33475929-D1559C30-A497-47DA-A989-319715BD1949Q33581390-94986509-6703-4AD7-BCC8-24F5AAB6CCC1Q33789201-A27C0C40-6282-4B8B-B272-5A7E2848942EQ33900049-4A1FE29E-8F8C-4A8E-A7AE-1A0D445320A2Q33911381-8CD65A94-56A4-4855-8EAA-A20E26638545Q33977523-F47D77B3-8A5A-41F2-ADD2-6A98D8D26481Q33977536-439C4B50-25DF-471F-A764-E61AC1A67733Q33977543-DA6897B3-D973-4B4E-8D2D-C44FB9F96990Q33978286-22C6D355-F800-4B8E-8440-13714F11E927Q33978360-695944F8-D2EE-49AF-9742-BDC867298D45Q34023510-1C5E3C55-17C8-4D54-BDAA-D33BE1826E43Q34211155-31CE2371-1464-4AB8-9CE8-59CFADB52E8AQ34389358-D67A7E2B-0BB6-4718-8183-5215A64AA2F0Q34417815-BDF3B4F8-55B1-4C14-BB3F-E13E4790153BQ34421944-77E25A98-7208-466B-BA5D-3D3A6C308F65Q34490592-E83481D9-6DED-4A4E-A6E0-A401F6A948EFQ34497901-7411366B-6D35-45E4-8A59-D7A5C453A842Q34557490-7A3B1F44-223A-4660-A5DE-733DB719598DQ34570396-56189982-7086-4B0D-B5D7-3A01533BAA0FQ34617845-5131FE52-5963-4417-AD84-57DA29EF13ECQ34617864-4185B407-A17D-4928-9A16-FEB44D03B0E2Q34617892-1E93CE73-BA37-4FB0-B5BD-ECBB3BD0E45EQ34617936-6FFC0CAB-881B-4E07-BEF1-30A113D73BB7Q34617956-5A62E430-0A30-4D32-81B3-34CC2D19495BQ34748485-0DF681FB-49C3-49A4-AC58-2ADED5062A6AQ34782101-5FF2DD47-C35F-454B-A147-EFA00C4A4A09Q34960686-42E6FDF1-F3C7-4D35-B37E-2B279995AE39Q35051528-B4BDCA8D-3154-415C-9723-81AE1AFFF301Q35380592-077F6F4E-65BC-4690-B794-BA54B6A56DF1Q35441262-79D9EDEA-F86D-4D99-8D0A-8D6358E1B4C6Q35627720-492C905B-67F7-4BB7-A391-53844080DE50Q35689824-DAD11E91-9753-4017-9B5E-BBEB1698C860Q35829609-3D0D35C4-142B-4917-819A-D269AEF168A4Q35855513-C1FD641B-D524-4E42-B511-58298C6877D4
P2860
Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Gonadotropin-releasing hormone ...... nonmetastatic prostate cancer.
@ast
Gonadotropin-releasing hormone ...... nonmetastatic prostate cancer.
@en
type
label
Gonadotropin-releasing hormone ...... nonmetastatic prostate cancer.
@ast
Gonadotropin-releasing hormone ...... nonmetastatic prostate cancer.
@en
prefLabel
Gonadotropin-releasing hormone ...... nonmetastatic prostate cancer.
@ast
Gonadotropin-releasing hormone ...... nonmetastatic prostate cancer.
@en
P2093
P356
P1476
Gonadotropin-releasing hormone ...... nonmetastatic prostate cancer.
@en
P2093
Chris L Pashos
Jane Brandman
Marc Botteman
Matthew R Smith
Won Chan Lee
P304
P356
10.1200/JCO.2004.00.6908
P407
P577
2005-11-01T00:00:00Z